BeOne Medicines Ltd
06160
Company Profile
Business description
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeOne is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeOne runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeOne’s revenue.
Contact
c/o BeOne Medicines I GmbH
Aeschengraben 27
21st Floor
Basel4051
CHET: +41 616851900
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
11,000
Stocks News & Analysis
stocks
ChatGPT enters the retail space and one company surges
Investors cheer the ability to purchase directly from ChatGPT.
stocks
Alibaba fair value increases by 49%
Stronger-than-expected AI demand internationally and domestically.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,135.90 | 19.50 | -0.21% |
| CAC 40 | 7,862.46 | 18.41 | -0.23% |
| DAX 40 | 23,791.29 | 46.23 | 0.19% |
| Dow JONES (US) | 46,316.07 | 68.78 | 0.15% |
| FTSE 100 | 9,317.09 | 17.25 | 0.19% |
| HKSE | 26,855.56 | 232.68 | 0.87% |
| NASDAQ | 22,591.15 | 107.09 | 0.48% |
| Nikkei 225 | 44,932.63 | 111.12 | -0.25% |
| NZX 50 Index | 13,292.36 | 159.80 | 1.22% |
| S&P 500 | 6,661.21 | 0.00 | 0.00% |
| S&P/ASX 200 | 8,848.80 | 20.50 | -0.23% |
| SSE Composite Index | 3,882.78 | 20.25 | 0.52% |